-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a study on "New crown vaccine may cause a rare T cell-mediated autoimmune hepatitis" published in the Journal of Hepatology, a journal in the field of liver disease The paper, which was finalized on March 31, 2022, refers to a case report in Germany of a 52-year-old man who developed a bimodal flare of acute hepatitis after receiving 2 doses of the mRNA vaccine
In this regard, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) announced on April 8 that there is currently no evidence to support a causal relationship between the mRNA new crown vaccine and autoimmune hepatitis (AIH), and no update is currently required.
There is currently no evidence to support a causal relationship between the mRNA new crown vaccine and autoimmune hepatitis (AIH), and there is currently no need to update the product information for the vaccine
Autoimmune hepatitis (AIH) is a very rare chronic progressive liver inflammatory disease mediated by an autoimmune response, according to the PRAC meeting minutes
The European Medicines Agency (EMA) said it will continue to closely monitor any new situation reports and take appropriate measures if necessary